China Oncology ›› 2023, Vol. 33 ›› Issue (9): 834-843.doi: 10.19401/j.cnki.1007-3639.2023.09.004
• Article • Previous Articles Next Articles
JIN Yizi1,2(), LIN Mingxi1,2, ZHANG Jian1,2()
Received:
2023-05-29
Revised:
2023-08-30
Online:
2023-09-30
Published:
2023-10-01
Contact:
ZHANG Jian.
CLC Number:
JIN Yizi, LIN Mingxi, ZHANG Jian. Receptor discordance between primary breast cancer and liver metastases[J]. China Oncology, 2023, 33(9): 834-843.
Tab. 1
Baseline characteristics of the included patients [n (%)]"
Characteristic | Patients (N = 353) | Characteristic | Patients (N = 353) | |
---|---|---|---|---|
Age at diagnosis of primary breast cancer/year | Time between diagnosis of primary and metastatic disease/month | |||
Median (Q1-Q3) | 46 (39-54) | <3 | 25 (7.1) | |
Range | 22-82 | ≥3 | 328 (92.9) | |
TNM stage | DFI | |||
Ⅰ | 42 (11.9) | De novo stage Ⅳ | 46 (13.0) | |
Ⅱ | 130 (36.8) | ≤24 months | 134 (38.0) | |
Ⅲ | 135 (38.2) | >24 months | 173 (49.0) | |
Ⅳ | 46 (13.0) | Number of metastatic sites at initial diagnosis of metastatic breast cancer | ||
Histological type | One site | 173 (49.0) | ||
Invasive ductal | 323 (91.5) | Two or more sites | 180 (51.0) | |
Invasive lobular | 8 (2.3) | Visceral metastasis at initial diagnosis of metastatic breast cancer | ||
Other or not reported | 22 (6.2) | Yes | 318 (90.1) | |
Primary breast cancer subtype | No | 35 (9.9) | ||
HR-/HER2- | 43 (12.2) | Previous endocrine therapy before re-biopsy | ||
HR-/HER2+ | 52 (14.7) | Yes | 229 (64.9) | |
HR+/HER2- | 217 (61.5) | No | 124 (35.1) | |
HR+/HER2+ | 41 (11.6) | Previous anti-HER2 therapy before re-biopsy | ||
Liver metastasis subtype | Yes | 56 (15.9) | ||
HR-/HER2- | 69 (19.5) | No | 297 (84.1) | |
HR-/HER2+ | 58 (16.4) | Previous chemotherapy before re-biopsy | ||
HR+/HER2- | 190 (53.8) | Yes | 310 (87.8) | |
HR+/HER2+ | 36 (10.2) | No | 43 (12.2) |
Tab. 2
The receptor status of primary breast cancer and liver metastases in patients who underwent second liver re-biopsies"
Patient | Receptor status of primary breast cancer | Receptor status of first liver re-biopsy | Time point of first liver re-biopsy* | Receptor status of second liver re-biopsy | Timepoint of second liver re-biopsy* |
---|---|---|---|---|---|
1 | ER+/PR+/HER2- | ER+/PR-/HER2- | 100 | ER-/PR-/HER2- | 127 |
2 | ER+/PR+/HER2- | ER+/PR+/HER2- | 34 | ER+/PR-/HER2- | 43 |
3 | ER+/PR+/HER2- | ER+/PR+/HER2- | 22 | ER+/PR-/HER2- | 51 |
4 | ER+/PR+/HER2- | ER-/PR+/HER2- | 9 | ER-/PR-/HER2- | 19 |
5 | ER+/PR+/HER2- | ER+/PR-/HER2- | 25 | ER+/PR+/HER2- | 42 |
6 | ER+/PR+/HER2- | ER+/PR-/HER2- | 56 | ER+/PR-/HER2- | 84 |
7 | ER+/PR+/HER2- | ER+/PR+/HER2- | 97 | ER+/PR+/HER2- | 138 |
8 | ER+/PR+/HER2- | ER+/PR+/HER2- | 31 | ER-/PR-/HER2- | 47 |
9 | ER-/PR-/HER2+ | ER-/PR-/HER2- | 38 | ER-/PR-/HER2- | 55 |
Tab. 3
Univariate analyses of factors associated with receptor discordance"
Characteristic | ER status | PR status | HER2 status | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Concordant | Discordant | Pvalue | Concordant | Discordant | P value | Concordant | Discordant | Pvalue | |||
Age at initial diagnosis | 0.202 | 0.683 | 0.370 | ||||||||
≤50 | 184 | 39 | 137 | 86 | 214 | 9 | |||||
>50 | 100 | 30 | 77 | 53 | 122 | 8 | |||||
DFI | 0.730 | <0.001 | 0.379 | ||||||||
≤24 months | 107 | 27 | 96 | 38 | 129 | 5 | |||||
>24 months | 138 | 35 | 85 | 88 | 162 | 11 | |||||
De novo stage Ⅳ | 39 | 7 | 33 | 13 | 45 | 1 | |||||
Histological type | 0.678 | 0.023 | 0.198 | ||||||||
Invasive ductal | 259 | 64 | 190 | 133 | 306 | 17 | |||||
Other | 25 | 5 | 24 | 6 | 30 | 0 | |||||
Time between diagnosis of primary tumor and liver metastasis/month | 0.324 | 0.103 | 0.243 | ||||||||
<3 | 22 | 3 | 19 | 6 | 25 | 0 | |||||
≥3 | 262 | 66 | 195 | 133 | 311 | 17 | |||||
Previous endocrine therapy before re-biopsy | 0.728 | <0.001 | 0.305 | ||||||||
No | 101 | 23 | 102 | 22 | 120 | 4 | |||||
Yes | 183 | 46 | 112 | 117 | 216 | 13 | |||||
Previous anti-HER2 therapy before re-biopsy | 0.728 | 0.227 | 0.117 | ||||||||
No | 238 | 59 | 176 | 121 | 285 | 12 | |||||
Yes | 46 | 10 | 38 | 18 | 51 | 5 | |||||
Previous chemotherapy before re-biopsy | 0.807 | 0.100 | 0.115 | ||||||||
No | 34 | 9 | 31 | 12 | 43 | 0 | |||||
Yes | 250 | 60 | 183 | 127 | 293 | 17 |
Fig.4
The influence of receptor conversion on OS A: The Kaplan-Meier plot of triple-negative primary breast cancer; B: The Kaplan-Meier plot of HR+/HER2- primary breast cancer; C: The Kaplan-Meier plot of HR±/HER2+ primary breast cancer; D: The Kaplan-Meier plot of triple-negative metastatic breast cancer; E: The Kaplan-Meier plot of HR+/HER2- metastatic breast cancer; F: The Kaplan-Meier plot of HR±/HER2+ metastatic breast cancer. The dashed line indicates the median OS of each group."
[1] |
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
doi: 10.3322/caac.v71.3 |
[2] |
RUGO H S, RUMBLE R B, MACRAE E, et al. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline[J]. J Clin Oncol, 2016, 34(25): 3069-3103.
doi: 10.1200/JCO.2016.67.1487 pmid: 27217461 |
[3] |
CARDOSO F, PALUCH-SHIMON S, SENKUS E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)[J]. Ann Oncol, 2020, 31(12): 1623-1649.
doi: 10.1016/j.annonc.2020.09.010 |
[4] |
JI L, CHENG L, ZHU X, et al. Risk and prognostic factors of breast cancer with liver metastases[J]. BMC Cancer, 2021, 21(1): 238.
doi: 10.1186/s12885-021-07968-5 pmid: 33676449 |
[5] |
MA R, FENG Y L, LIN S, et al. Mechanisms involved in breast cancer liver metastasis[J]. J Transl Med, 2015, 13: 64.
doi: 10.1186/s12967-015-0425-0 pmid: 25885919 |
[6] |
SCHRIJVER W A M E, SUIJKERBUIJK K P M, VAN GILS C H, et al. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis[J]. J Natl Cancer Inst, 2018, 110(6): 568-580.
doi: 10.1093/jnci/djx273 pmid: 29315431 |
[7] |
AURILIO G, DISALVATORE D, PRUNERI G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases[J]. Eur J Cancer, 2014, 50(2): 277-289.
doi: 10.1016/j.ejca.2013.10.004 pmid: 24269135 |
[8] |
MODI S N, JACOT W, YAMASHITA T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
doi: 10.1056/NEJMoa2203690 |
[9] |
DENKERT C, SEITHER F, SCHNEEWEISS A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials[J]. Lancet Oncol, 2021, 22(8): 1151-1161.
doi: 10.1016/S1470-2045(21)00301-6 pmid: 34252375 |
[10] |
TARANTINO P, CURIGLIANO G, TOLANEY S M. Navigating the HER2-low paradigm in breast oncology: new standards, future horizons[J]. Cancer Discov, 2022, 12(9): 2026-2030.
doi: 10.1158/2159-8290.CD-22-0703 |
[11] |
WOLFF A C, SOMERFIELD M R, DOWSETT M, et al. Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-College of American Pathologists guideline update[J]. J Clin Oncol, 2023, 41(22): 3867-3872.
doi: 10.1200/JCO.22.02864 |
[12] |
ALLISON K H, HAMMOND M E H, DOWSETT M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update[J]. J Clin Oncol, 2020, 38(12): 1346-1366.
doi: 10.1200/JCO.19.02309 pmid: 31928404 |
[13] |
LIU J Q, DENG H R, JIA W J, et al. Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatment[J]. J Cancer Res Clin Oncol, 2012, 138(5): 837-842.
doi: 10.1007/s00432-012-1150-1 pmid: 22290394 |
[14] |
CURIGLIANO G, BAGNARDI V, VIALE G, et al. Should liver metastases of breast cancer be biopsied to improve treatment choice?[J]. Ann Oncol, 2011, 22(10): 2227-2233.
doi: 10.1093/annonc/mdq751 pmid: 21343379 |
[15] |
HOEFNAGEL L D, MOELANS C B, MEIJER S L, et al. Prognostic value of estrogen receptor α and progesterone receptor conversion in distant breast cancer metastases[J]. Cancer, 2012, 118(20): 4929-4935.
doi: 10.1002/cncr.27518 pmid: 22415862 |
[16] |
LIEDTKE C, BROGLIO K, MOULDER S, et al. Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer[J]. Ann Oncol, 2009, 20(12): 1953-1958.
doi: 10.1093/annonc/mdp263 pmid: 19596702 |
[17] |
DIECI M V, BARBIERI E, PIACENTINI F, et al. Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis[J]. Ann Oncol, 2013, 24(1): 101-108.
doi: 10.1093/annonc/mds248 pmid: 23002281 |
[18] |
LIN M X, JIN Y Z, LV H, et al. Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases[J]. Int J Cancer, 2023, 152(7): 1476-1489.
doi: 10.1002/ijc.v152.7 |
[19] |
LU Y J, TONG Y W, CHEN X S, et al. Association of biomarker discrepancy and treatment decision, disease outcome in recurrent/metastatic breast cancer patients[J]. Front Oncol, 2021, 11: 638619.
doi: 10.3389/fonc.2021.638619 |
[20] |
CURTIT E, NERICH V, MANSI L, et al. Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis[J]. Oncologist, 2013, 18(6): 667-674.
doi: 10.1634/theoncologist.2012-0350 pmid: 23723333 |
[21] |
DUCHNOWSKA R, DZIADZIUSZKO R, TROJANOWSKI T, et al. Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brain[J]. Breast Cancer Res, 2012, 14(4): R119.
doi: 10.1186/bcr3244 |
[22] |
MCGRANAHAN N, SWANTON C. Clonal heterogeneity and tumor evolution: past, present, and the future[J]. Cell, 2017, 168(4): 613-628.
doi: S0092-8674(17)30066-1 pmid: 28187284 |
[23] |
HU Z, SUN R, CURTIS C. A population genetics perspective on the determinants of intra-tumor heterogeneity[J]. Biochim Biophys Acta Rev Cancer, 2017, 1867(2): 109-126.
doi: 10.1016/j.bbcan.2017.03.001 |
[24] |
NAVIN N, KENDALL J, TROGE J, et al. Tumour evolution inferred by single-cell sequencing[J]. Nature, 2011, 472(7341): 90-94.
doi: 10.1038/nature09807 |
[25] |
MITTENDORF E A, WU Y, SCALTRITI M, et al. Loss of HER2 amplification following trastuzumab-based neoadjuvant systemic therapy and survival outcomes[J]. Clin Cancer Res, 2009, 15(23): 7381-7388.
doi: 10.1158/1078-0432.CCR-09-1735 pmid: 19920100 |
[26] |
HU Z, LI Z, MA Z C, et al. Multi-cancer analysis of clonality and the timing of systemic spread in paired primary tumors and metastases[J]. Nat Genet, 2020, 52(7): 701-708.
doi: 10.1038/s41588-020-0628-z pmid: 32424352 |
[27] |
MAYNADIER M, NIRDÉ P, RAMIREZ J M, et al. Role of estrogens and their receptors in adhesion and invasiveness of breast cancer cells[J]. Adv Exp Med Biol, 2008, 617: 485-491.
doi: 10.1007/978-0-387-69080-3_48 pmid: 18497073 |
[1] | WU Han, YANG Zhangru, FENG Wen, ZENG Wanqin, GUO Jindong, LI Hongxuan, WANG Changlu, WANG Jiaming, LÜ Changxing, ZHANG Qin, YU Wen, CAI Xuwei, FU Xiaolong. The efficacy and prognosis analysis after stereotactic body radiotherapy for multiple primary early-stage lung cancer [J]. China Oncology, 2023, 33(9): 844-856. |
[2] | CHEN Jinjuan, WANG Xingran, LI Wenzhi, CHENG Yu, SUN Yihua, TAO Xiang, MA Fenghua, SUN Li, ZHAO Hongbo, LU Xin. Conservative surgery in stage I placental site trophoblastic tumor: a report of 10 cases and literature review [J]. China Oncology, 2023, 33(9): 857-865. |
[3] | SUN Yang, WANG Lian, ZHAO Meng, ZHANG Xiaofeng, GENG Zhijun, WANG Yueyue, SONG Xue, ZUO Lugen, LI Jing, HU Jianguo. The prognostic value of high expression of FKBP1A in gastric cancer and the regulatory effect of targeted PI3K/AKT on glucose metabolism [J]. China Oncology, 2023, 33(8): 726-739. |
[4] | JIANG Lin, LIU Qiying, JIA Liqing, ZHANG Jing, CHANG Heng, XUE Tian, REN Min, BAI Qianming, ZHU Xiaoli, ZHOU Xiaoyan. Retrospective study on MGMT methylation status and its clinical significance in gliomas [J]. China Oncology, 2023, 33(8): 740-750. |
[5] | YANG Zhongyi, XU Xiaoping, WANG Mingwei, ZHANG Yongping, YANG Jianwei, CHEN Yue, XU Wengui, LI Yaming, ZHANG Yingjian, SONG Shaoli. The specification and use of 18F-FES PET in breast cancer [J]. China Oncology, 2023, 33(8): 801-808. |
[6] | WANG Ruoxi, JI Peng, GONG Yue, CHEN Sheng. Response rate and clinical outcome of HER2-low breast cancer after neoadjuvant therapy: a single-center retrospective study [J]. China Oncology, 2023, 33(7): 686-692. |
[7] | WU Siyu, LI Junjie, SHAO Zhimin. Development history and research progress of sentinel lymph node biopsy in breast cancer [J]. China Oncology, 2023, 33(6): 551-559. |
[8] | BI Zhao, WANG Yongsheng. New concept of de-escalation management strategy in breast cancer patients with 1-2 positive sentinel lymph nodes [J]. China Oncology, 2023, 33(6): 560-565. |
[9] | ZHAO Qian, LING Yunxiao, LIU Guangyu. Recent advances and perspectives in the application of repeat sentinel lymph node biopsy in breast cancer patients underwent breast-conserving surgery [J]. China Oncology, 2023, 33(6): 566-573. |
[10] | CONG Binbin, CAO Xiaoshan, WANG Chuanjian, QIU Pengfei, SUN Xiao, CHEN Peng, LIU Yanbing, ZHAO Tong, ZHANG Zhaopeng, SHI Zhiqiang, BI Zhao, WANG Yongsheng. Feasibility analysis of sentinel lymph node biopsy in breast cancer with axilla negative evaluation by physical examination but suspicious lymph nodes finding on preoperative imaging and metastasis confirmed with biopsy [J]. China Oncology, 2023, 33(6): 574-580. |
[11] | REN Hengyu, HAO Shuang, CHEN Jiajian, YANG Benlong, CAO Ayong, LIU Guangyu, SHAO Zhimin, WU Jiong. Current status and focus of breast reconstruction research in China and abroad: a bibliometric study [J]. China Oncology, 2023, 33(6): 581-588. |
[12] | ZOU Ting, LIU Xiaowen. Analysis of efficacy of hepatectomy and prognostic risk factors in patients with gastric cancer with synchronous liver metastasis [J]. China Oncology, 2023, 33(6): 605-612. |
[13] | CHEN Luyan, WANG Lixue, FU Peifen. The value of surgery in the patients with de novo stage Ⅳ breast cancer [J]. China Oncology, 2023, 33(5): 431-436. |
[14] | ZUO Xueliang, CHEN Zhiqiang, DONG Runyu, WANG Zhixiong, CAI Juan. The value of combined detection of LDHA and PD-L1 in predicting the efficacy and prognosis of advanced gastric cancer patients treated with PD-1 inhibitor [J]. China Oncology, 2023, 33(5): 460-468. |
[15] | YANG Wenxiao, GUO Linwei, LING Hong, HU Xin. Characterization of immune microenvironment identifies prognostic and immunotherapy benefit for trastuzumab-based therapy [J]. China Oncology, 2023, 33(5): 484-498. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd